 |
JW Pharmaceutical (Photo courtesy of JW Pharmaceutical) |
[Alpha Biz= Reporter Kim Jisun] On the 23rd, JW Pharmaceutical announced that its subsidiary, JW Shinyak, has been hit with a three-month sales suspension for 56 drug products.
According to the Ministry of Food and Drug Safety (MFDS), JW Shinyak was found to have provided economic benefits worth approximately 800 million won to promote the sale of drugs, including "Eylea Eye Drops," to medical institutions between 2013 and 2019.
As a result, on September 23rd, the MFDS imposed the suspension on JW Shinyak, which will take effect from October 7, 2024, to January 6, 2025.
The sales of these 56 products generated 35.1 billion won in revenue last year, accounting for 33.7% of JW Shinyak's total revenue.
AlphaBIZ Kim Jisun(stockmk2020@alphabiz.co.kr)
